 |
 |  |
|
| The ISPOR mission is to translate pharmacoeconomics and outcomes research into practice. We encourage health care practitioners, health care purchasers, and health care decision-makers, as well as pharmacoeconomic and outcomes researchers to attend this meeting. | In this program, SPECIAL TRACKS are identified for the following:
|
 | Health care practitioner (physician, pharmacist, nurse, other health care professionals) |
 | Health care decision-maker & purchaser (health plans, insurance companies, government) |
 | Outcomes (quality-of-life) researchers |
 | Pharmacoeconomic (health economic) researchers |
| Choose your TRACK and follow the symbol in the program to help you select presentations that match your interest. |
| Tuesday, May 25, 1999 |
|
| 7:00AM - 8:00AM | CONTINENTAL BREAKFAST IN FOYER |
| 7:00AM - 8:00AM | CONTRIBUTED WORKSHOP SESSION 2 PRESENTER MEETING |
| 7:00AM - 8:00AM | ISPOR FACULTY NETWORKING FORUM BREAKFAST (open invitation) |
| 7:00AM - 8:00AM | ISPOR INSTITUTIONAL COUNCIL BREAKFAST (invitation only) |
| 8:00AM - 8:15AM | SECOND GENERAL SESSION
REMARKS
Jon Clouse MS, Executive Vice President, Ingenix Pharmaceutical Services, Eden Prairie, MN, USA, Fourth Annual International Meeting Chair
ISPOR INCOMING PRESIDENTIAL REMARKS
Bryan Luce PhD, MBA, CEO of MEDTAP International, Bethesda, MD, USA,
1998-99 ISPOR President-elect |
|
8:15AM - 10:15AM
 | "LOOKING BEYOND DRUG ACQUISITION COSTS: WHAT WORKS AND WHAT DOESN'T"
Second General Session Discussion Leader: Nicolaas Otten PharmD, Director, Pharmaceutical & Extramural Research, Canadian Coordinating Office for Health Technology, Ottawa, Ontario, Canada
Keynote Speaker: David Henry MD, Faculty of Medicine and Health Sciences, University of Newcastle, Callaghan, New South Wales, Australia
Drug policy programs that have included cost-effectiveness analyses in the decision process will be examined. The strengths and weaknesses of these programs will be presented.
Responders: • Grant Bagley MD, JD, Director, Coverage & Analysis Group, Health Care Financing Administration, Baltimore, MD, USA (invited) • Jennifer Elston Lafata PhD, Acting Director, Center for Clinical Effectiveness, Henry Ford Health Systems, Detroit, MI, USA
Dr. Bagley and Dr. Elston Lafata will respond to Dr. Henry's comments on the Australian experience utilizing health economics to make health care policy decision. The willingness of a community to pay the incremental costs for additional benefits promised by new drugs, maintaining equity of access, the importance of total expenditure, and community input into determining priorities will be debated. |
| 10:15AM - 11:00AM | AWARDS PRESENTATION
Presenters: Robert Epstein MD, MS, Senior Vice President, Merck-Medco Managed Care, Montvale, NJ, USA, and 1998-99 ISPOR President and
Kent Summers PhD, Health Outcomes Research Consultant, Eli Lilly & Company, Indianapolis, IN, USA and ISPOR Awards Committee Chair |
|
| 'TALKING' POSTER DISCUSSION GROUPS are organized discussions of selected poster presentations. Poster Presentations are grouped by a specific subject (a disease, a methodology, or an issue). During the 'TALKING' POSTER DISCUSSION GROUP session, each presenter in the grouping has 2-3 minutes to present a key finding/issue from his/her poster. A discussion leader will then compare and contrast findings/issues and will ask presenters to comment on other posters in the group. |
|
|
| 11:00 - 12:00AM | 'TALKING' POSTERS DISCUSSION GROUPS - CONTRIBUTED PAPERS |
|
| | COST OF ILLNESS |
| | TPIL1
| ANALYSIS OF DIRECT, INDIRECT AND TOTAL COSTS OF ASTHMA FROM PATIENT SURVEY DATA
Johnson KA, Ernst RL, and Ogostalick AE, University of Southern California, Los Angeles, CA, USA |
| | TPIL2
| THE COST OF TREATING PARKINSON'S DISEASE (PD) IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM
McCombs JS, Nichol MB, Lyu RR, Shi L, Department of Pharmaceutical Economics & Policy, University of Southern California, CA, USA |
| | TPIL3
| THE MEDICAL COST OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS: METHODS AND EVIDENCE
Lee DW2, Meyer J1, Clouse J1, 1Ingenix, Eden Prairie, MN, USA; 2GD Searle, Skokie IL, USA |
| | TPIL4
| SCHIZOPHRENIA CARE ASSESSMENT PROGRAM (SCAP) - INITIAL FINDINGS ON HEALTH CARE RESOURCE UTILISATION IN AUSTRALIA
Gibson J, Hristova L, Davey P, Montgomery B, Kulkani J, de Castella A, M-TAG, Chatswood, New South Wales, Australia |
| | TPIL5
| EVALUATION OF MEDICAL RESOURCE UTILIZATION IN ALZHEIMER'S DISEASE
Morris LS, Lichtenstein M, Smith J, IMS HEALTH, Plymouth Meeting, PA, USA |
| | TPIL6
| ESTIMATING THE ECONOMIC IMPACT (EI) OF VIRAL MENINGITIS (VM) IN THE UNITED STATES (US)
Parasuraman TV1, Deverka PA2, Toscani MR1, on behalf of the Meningitis Consensus Panel*, 1Hastings Healthcare Group, Inc., Pennington, NJ, USA; 2Merck-Medco Managed Care, Montvale, NJ, USA |
| | TPIL7
| MEDICAL RESOURCE USE AND PAYER COSTS OF INPATIENT AND OUTPATIENT CARE RELATED TO EPILEPSY
Griffiths RI, Wargo MC, Friedman M, Covance Health Economics and Outcomes Services Inc., Washington, DC, USA |
|
| | SCREENING PROGRAMS |
| | TPS1
| A COST EFFECTIVE APPROACH FOR UNIVERSAL COLON CANCER SCREENING IN A MANAGED CARE MODEL
Sampson JM, Schmitt JB, Dept of Veterans Affairs, Alexandria, LA, USA |
| | TPS2
| COST ANALYSIS OF A DIAGNOSTIC SCREENING TO DIFFERENTIATE 30 TO 45 YEARS OLD PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS
Kilburg A, Bruchhausen Y, Thomas J, Rychlik R, Institute of Empirical Health Economics, Burscheid, Germany |
| | TPS3
| ESTIMATING THE VALUE OF DOUBLE READING IN MAMMOGRAPHY SCREENING
Semroc GN, Botteman MF, Dever MT, PAREXEL, Alexandria, VA, USA |
| | TPS4
| COMPARISON OF THE EFFECTIVENESS OF INNOVATIVE PROGRAMS TO ENHANCE MAMMOGRAPHY COMPLIANCE: A META-ANALYSIS
Wu H1, Fung M2, Chan W1, Lairson D1, 1UT Houston School of Public Health, Houston, TX, USA; 2Lilly Research Laboratories, Indianapolis, IN, USA |
| | TPS5
| COST-EFFECTIVENESS ANALYSIS OF GENETIC TESTING FOR BREAST CANCER
Luo M, Hay J, Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA, USA |
| | TPS6
| COST-EFFECTIVENESS OF SCREENING AND TREATING DIABETIC RETINOPATHY IN TYPE I DIABETICS
Liu G, Kamath T, Bautisa J, Binman O, De Jesus R, Hom K, Madenjian C, Lalavia M, Okita M, Patel D, Parikh N, Tjauw J, Takami S, University of Southern California, Los Angeles, CA, USA |
| | TPS7
| PREVENTION OF RUBELLA INFECTION IN CRUISE SHIP CREW MEMBERS: A COST ANALYSIS COMPARING TWO INTERVENTIONS
Burnett CL, Reef S, Deuson R, Kramarz P, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA |
|
| | COMPLIANCE PROGRAMS |
| | TPCP1
| THE ROLE OF COMPLIANCE IN THERAPY CHANGES AMONG NEWLY DIAGNOSED DIABETIC PATIENTS
Cox ER1, Okamoto LJ2, 1University of Arizona, College of Pharmacy, Tucson, AZ, USA; 2NDC Health Information Services, Phoenix, AZ, USA |
| | TPCP2
| PERCENTAGE OF ANTI-HYPERTENSIVE DRUGS "FILLED AS INTENDED" COMPARING PHARMACY CLAIMS AND MEDICAL RECORDS DATA
Connors H, Cleary M, Clouse J, Ingenix, Minneapolis, MN, USA |
| | TPCP3
| PATIENT COMPLIANCE, QUALITY OF LIFE AND SATISFACTION AFTER INTENSIVE OUTPATIENT COUNSELLING
Juzba M, Hay J, University of Southern California School of Pharmacy, Department of Pharmaceutical Economics and Policy, Los Angeles, CA, USA |
| | TPCP4
| DISCRETE CHOICE MODELING ON PATIENT PERCEIVED COMPLIANCE: ANALYSIS OF PATIENT'S HEALTH BELIEF PERSPECTIVE
Sengupta N, Nichol MB, Cattaneo M, Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, California, USA |
| | TPCP5
| THE COST OF DISCONTINUATION OF ANTIHYPERTENSIVE DRUG THERAPY IN A MEDICAID POPULATION
Venturini F1, Nichol MB1, McCombs JS1, Sengupta N1, Kamath T1, Tannous RE2, 1University of Southern California, Los Angeles, CA, USA, 2PrudentRx, Culver City, CA, USA |
| | TPCP6
| THE ROLE OF ALTERNATIVE ANTIHYPERLIPIDEMIC DRUGS: PATIENT COMPLIANCE, HEALTHCARE UTILIZATION, AND
HEALTHCARE COSTS
Shi L, Nichol MB, Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA, USA |
| | TPCP7
| A PATH ANALYTIC STUDY OF THE ASSOCIATION BETWEEN PHARMACISTS' DIRECTIVE GUIDANCE BEHAVIORS, PATIENT
SATISFACTION, PATIENT COMPLIANCE AND HEALTH-RELATED QUALITY-OF-LIFE
Singhal PK, Gupchup GV, Raisch DW, University of New Mexico College of Pharmacy, Albuquerque, NM, USA |
|
| | DECISION ANALYTIC MODELING |
| | TPDM1
| ASSESSING THE PREDICTIVE ABILITY OF A DETERMINISTIC MODEL AND STOCHASTIC MODEL
Krueger KP1, Cox ER2, Draugalis JR2, Slack MK2, 1Auburn University, Auburn, AL, USA; 2The University of Arizona, Tucson, AZ, USA |
| | TPDM1
| COST-EFFECTIVENESS OF INCREASING WARFARIN USAGE FOR STROKE PROPHYLAXIS IN PATIENTS WITH ATRIAL FIBRILLATION
Touchette DR, Keys PJ, Racine E, Massanari RM, Andersen J, Stevenson J, and the IAD Task Force, Wayne State University, Detroit, MI, USA; Detroit Medical Center, Detroit, MI, USA |
| | TPDM1
| IS THERE POTENTIAL BIAS IN MODELLING WITH DECISION ANALYTIC SOFTWARE OR MATRIX PROGRAMMING?
Nichol G, Wells GA, University of Ottawa, Ottawa, Canada |
| | TPDM1
| MODELING LIFETIME TREATMENT COSTS OF HIV/AIDS PATIENTS
Pleil AM1, Kempel A2, Willke RJ3, 1Pharmacia & Upjohn, Stockholm, Sweden; 2Pharmametrics GmbH, Freiburg, Germany; 3Pharmacia & Upjohn, Kalamazoo, MI, USA |
| | TPDM1
| COST-BENEFIT ANALYSIS OF AN INTRA-UTERINE LEVONORGESTREL-RELEASING DEVICE MIRENA VERSUS HYSTERECTOMY FOR WOMEN WITH MENORRHAGIA
Milne RJ1,2, Farquhar CF3, 1Health Outcomes Associates Ltd; 2University of Auckland, Auckland, New Zealand |
| | TPDM1
| DETERMINING COST DRIVERS IN A COST-EFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR OVERACTIVE BLADDER
Arikian SA1,2, Tarride JE2, Casciano R2, Corey R2,3, Casciano J2, 1Columbia University , New York, NY, USA; 2The Analytica Group, New York, NY, USA; 3University of the Sciences in Philadelphia, Philadelphia, PA, USA |
| | TPDM1
| COST OF ISCHEMIC STROKE TREATMENT BY FUNCTIONAL STATUS: A MODEL COMPARING CITICOLINE TO STANDARD CARE
Wilson DA, Gammans RE, Evans CJ, Boston, MA, USA |
|
| 12:00PM - 1:30PM | POSTER PRESENTATIONS, EXHIBITS, AND REFRESHMENTS IN EXHIBIT HALL
Click here for Poster Presentation Titles |
|
| 1:30 - 1:30PM | 'TALKING' POSTERS DISCUSSION GROUPS - CONTRIBUTED PAPERS |
|
| | ECONOMIC ANALYSIS OF CLINICAL TRIALS |
| | TPCT1
| ECONOMIC ANALYSIS OF TIRILAZAD MESYLATE FOR ANEURYSMAL SUBARACHNOID HEMORRHAGE: ECONOMIC EVALUATION COMBINING FOUR PHASE III CLINICAL TRIALS
Polsky D1, Yen WM1, Willke RJ2, Glick H1, 1University of Pennsylvania, Philadelphia, PA, USA; 2Pharmacia and Upjohn Inc., Kalamazoo, MI, USA |
| | TPCT2
| COST-EFFECTIVENESS OF ABCIXIMAB IN PERCUTANEOUS CORONARY INTERVENTION PATIENTS: RESULTS FROM A META-ANALYSIS
Mauskopf JA1, Bala MV2, Hermiller JB3, Barber BL4, Anderson KM2, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Centocor, Inc., Malvern, PA, USA; 3Nasser, Smith and Pinkerton Cardiology, Inc., Indianapolis, IN, USA; 4Eli Lilly and Company, Indianapolis, IN, USA |
| | TPCT3
| COST EFFECTIVENESS OF ANTIMALARIAL TREATMENT OF QUININE PLUS DOXYCYCLINE VERSUS ARTEMISININ PLUS DOXYCYCLINE IN PHUOC LONG HOSPITAL, VIETNAM
Sooksriwong C2, Thuy HV1, Sathirakul K2, 1Hanoi College of Pharmacy, Hanoi, Vietnam; 2Faculty of Pharmacy, Mahidol University, Bangkok, Thailand |
| | TPCT4
| COST-EFFECTIVENESS OF RABEPRAZOLE VERSUS RANITIDINE IN REFLUX ESOPHAGITIS
Ofman JJ1, Yamashita BD2, Siddique RS3, Larson LR2, Willian MK3, 1Cedars Sinai/Zynx Health Inc, Los Angeles, CA, USA; 2Ovation Research Group, Highland Park, IL, USA; 3Janssen Pharmaceutica, Titusville, NJ, USA |
| | TPCT5
| TREATMENT OF DIABETIC FOOT ULCERS WITH TOPICAL RECOMBINANT GROWTH FACTOR GEL GEL ACHIEVES HIGHER HEALING RATES AND RESULTS IN LOWER PROJECTED COSTS OF CARE
Martens L1, Zagari M1, Gagnon D1, Wieman TJ2, 1ICOM Health Economics, Johnson & Johnson, Raritan, NJ, USA; 2Department of Surgical Oncology, University of Louisville, Louisville, KY, USA |
| | TPCT6
| INCREASED UPPER GASTROINTESTINAL (UGI) DISTRESS AMONGST ARTHRITIS PATIENTS TREATED WITH NSAIDS AS COMPARED TO CELECOXIB AND PLACEBO
Burke TA2, Goldstein JL1, Pettitt AD3, Maurath CJ2, Zhao SZ2, Zabinski RA2, 1University of Illinois at Chicago, Chicago, IL, USA; 2G.D. Searle, Skokie, IL, USA; 3Pfizer Inc., New York, NY, USA |
| | TPCT7
| CEFPODOXIME PROXETIL 100 MG VERSUS CEFPODOXIME PROXETIL 200MG IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS IN ADULT PATIENTS
Wilson JP1, Johnsrud MT1, Shepherd MD1, Pleil AM2, 1University of Texas, Austin,TX, USA; 2Pharmacia & Upjohn AB, Stockholm, Sweden |
|
| | QUALITY OF LIFE INSTRUMENTS |
| | TPQL1
| DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A QUALITY OF LIFE QUESTIONNAIRA IN URINARY INCONTINENCE (CONTILIFE®)
Girod1, McCarthy C2, Marrel A1, De la Loge C3, Marquis P1, 1Mapi Values, Lyon, France, 2Synthelabo, France, 3Mapi, France |
| | TPQL2
| SF-36 AS A PREDICTOR OF HEALTH STATES
Reed PJ1, Moore DD2, 1University of Tennessee-Memphis, Memphis, TN, USA; 2Clemson University, Clemson, SC, USA |
| | TPQL3
| QUALITY OF LIFE IN CROHN DISEASE: A PROSPECTIVE, LONGITUDINAL STUDY IN 231 PATIENTS
Chircop C1, Blondel-Kucharski F2, Marquis P1, Colombel JF2, Gendre JP3 and GETAID, 1Mapi Values, Lyon, France, 2Service d'Hépato-Gastroentérologie, CHU Lille, France; 3Service d'Hépato-Gastroentérologie, Höpital Rothschild, France |
| | TPQL4
| A TIME SERIES AND PANEL DATA APPROACH TO CROSS-TRANSLATE DESCRIPTIVE HEALTH STATUS TO HEALTH PREFERENCE IN PATIENTS WITH CHRONIC DISEASES
Sengupta N, Nichol MB, Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, California, USA |
| | TPQL5
| A REVIEW AND EVALUATION OF THE EMEA DOCUMENTS WITH REFERENCE TO QUALITY OF LIFE (QOL) ASSESSMENT
Apolone G1, Brunetti M1, DeCarli G2, Acquadro C3 for the European Regulatory Issues on QoL Assessment (ERIQA) Group, 1Mario Negri Institute, Milano, Italy; 2Glaxo Wellcome, Verona, Italy; 3Mapi Research Institute, Lyon, France |
| | TPQL6
| THE PERFORMANCE OF A GENERIC MEASURE (EQ-5D) IN ASSESSING MENTAL HEALTH OUTCOMES
Kind P1, Palmer S1, Boyd T2, Corson M2, Hurst N3, 1Centre for Health Economics, University of York, York, England; 2North Manchester General Hospital, Manchester, England; 3Western General Infirmary, Edinburgh, Scotland |
| | TPQL7
| THE EFFECT OF ORDER OF ADMINISTRATION OF GENERIC AND DISEASE SPECIFIC QUALITY OF LIFE QUESTIONNAIRES
Lee TA, Sullivan SD, University of Washington, Seattle, WA, USA |
|
| | RETROSPECTIVE DATABASE ANALYSIS |
| | TPRD1
| PHARMACOECONOMIC ANALYSIS OF WARFARIN VERSUS ENOXAPARIN USED PROPHOLACTICALLY IN HIP SURGERY
Egan T, University of the Sciences in Philadelphia, Philadelphia, PA, USA; Clinical Pharmacotherapeutics, Inc., Philadelphia, PA, USA |
| | TPRD2
| INCIDENCE OF SMALL-BOWEL OBSTRUCTION AND ADHESIOLYSIS FOLLOWING OPEN COLORECTAL AND GENERAL SURGERY
Beck DE1, Opelka FG1, Bailey HR2, Rauh SM3, Pashos CL4, 1Ochsner Clinic, New Orleans LA, USA; 2University of Texas, Houston TX, USA; 3Rochester Colorectal Surgeons, Rochester NY, USA; 4Abt Associates Clinical Trials, Cambridge, MA, USA |
| | TPRD3
| OUTCOMES OF TREATMENT OF UNCOMPLICATED HYPERTENSION WITH DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS
Lenert LA1, Linde-Zwirble W2, Newbold III R2, Korenblat BM3, Smith ME3, Pomerantz K3, Chung KC3, 1Department of Veterans Affairs, San Diego, CA, USA; 2Health Process Management, Doylestown, PA, USA; 3Bayer Corporation, Pharmaceutical Division, West Haven, CT, USA |
| | TPRD4
| the cost-EFFECTIVENESS OF IMMUNOSUPPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION
Clark T, Shih YCT, Dupuis B, Hartzema A, University of North Carolina School of Pharmacy, Department of Pharmaceutical Policy and Evaluative Science, Chapel Hill, NC, USA |
| | TPRD5
| USING HOSPITAL CLAIMS TO TRACK PRACTICE PATTERNS, Outcomes, AND COSTS IN PERCUTANEOUS CORONARY
INTERVENTIONS (PCI)
Karweit J, Cascade E, Lin N, The Lewin Group, Fairfax, VA, USA |
| | TPRD6
| TOTAL HEALTHCARE UTILIZATION AND COSTS ASSOCIATED WITH MIGRAINE IN A MEDICAID POPULATION
Joish VN, Cady PS, Culbertson VL, College of Pharmacy, Idaho State University, Pocatello, ID, USA |
| | TPRD7
| ESTIMATING LIFE-EXPECTANCY IN POST-ACUTE CORONARY SYNDROMES: THE IMPORTANCE OF TWO-COMPONENT SURVIVAL MODELS
Nelson CL1, Eisenstein EL1, Shaw LK1, Hakim Z2, Mark DB1, 1Duke Clinical Research Institute, Durham, NC, USA; 2Roche Global Pharmacoeconomic Research, Palo Alto, CA, USA |
|
| | INDIRECT COSTS |
| | TPIC1
| INDIRECT COSTS OF MIGRAINEURS: THREE DIFFERENT APPROACHES TO VALUING LOST WORKPLACE PRODUCTIVITY
Thornhill JC, Lofland JH, Thomas Jefferson University, Philadelphia, PA, USA |
| | TPIC2
| IMPACT OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD): A SURVEY OF PRIMARY CAREGIVERS
Jackson SE, Peeples P, Alza Corporation, Palo Alto, CA, USA |
| | TPIC3
| The Productivity Costs of Allergic Rhinitis
Crystal-Peters J, Crown B, Goetzel R, The Medstat Group, Inc., Washington, DC, USA |
| | TPIC4
| QUANTIFICATION OF INDIRECT BENEFITS FROM MORBIDITY AND MORTALITY REDUCTION - APPLICATION TO PHARMACY SERVICES PROGRAM EVALUATION
Lai L1, Sorkin A2, 1Nova Southeastern University, Ft. Lauderdale, FL, USA, 2Johns Hopkins University/University of Maryland, Baltimore, MD, USA |
| | TPIC5
| TELEPHONY AS A COST EFFICIENT METHOD FOR ASSESSING HEALTH CARE UTILIZATION (HCU) AND PRODUCTIVITY LOSS (PL) IN AN EMPLOYED POPULATION
Parasuraman TV1, Pizzi LT1, Toscani MR1, Patterson R1, Coleman MJ2, Decker DL1, 1Hastings Healthcare Group, Inc., Pennington, NJ, USA; 2Wyeth-Ayerst Pharmaceuticals, St. Davids, PA, USA |
|
| 2:30PM - 3:00PM | REFRESHMENTS IN EXHIBIT HALL |
|
| 3:00 - 3:50PM | CONTRIBUTED WORKSHOPS - SESSION 2 |
|
| | WPE4
| AN ELECTRONIC TOOL FOR EMPIRIC ASSESSMENT OF DISEASE RISK, CATEGORIZATION OF PATIENTS AT RISK AND MONITORING OF OUTCOMES
Ambegaonkar A, Day D, Brandman J, Livengood K, Lubowski TJ, Nobles-Knight D, Van Vleet J, Woon J, Yamaga C, Clinical Pharmacy Outcomes Research, Pfizer Inc., New York, NY, USA |
| | WPE5
| ANALYSES OF OUTCOME DOMAINS IN SCHIZOPHRENIA: METHODOLOGIES AND RESULTS FROM THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)
Russo, P1, Mark, T1, Vasey, J2, Burrell L1, Diran, R1, Johnstone B3, 1The MEDSTAT Group, Inc., Washington, DC, USA; 2The Pennsylvania State University, State College, PA, USA; 3Eli Lilly and Company, Indianapolis, IN, USA |
| | WPE6
| PHARMACOECONOMICS OF SCREENING AND TESTING
Shih YCT1, Biddle AK1, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, Halpern MT, 2MEDTAP International, Bethesda, MD, USA |
| | WTG3
| WHAT EVERY OUTCOMES RESEARCHER SHOULD KNOW ABOUT WOMEN'S HEALTH RESEARCH
Frank L1, Greenberger P2, Finnegan L3, Panetta J4, 1MEDTAP International, Bethesda, MD, USA; 2Society for the Advancement of Women's Health Research, Washington DC, USA; 3National Institutes of Health, Bethesda, MD, USA; 4Lilly Center for Women's Health, Indianapolis, IN, USA |
| | WTG4
| ECONOMIC EVALUATION OF PHARMACEUTICALS IN ISRAEL - CURRENT AND FUTURE NATIONAL POLICY
Shani S, Shemer J, Ministry of Health, Jerusalem, Israel |
| | WDM2
| EXPERIENCE WITH RESEARCH DATA
Jackson B, Blue Cross and Blue Shield of Massachusetts, Boston, MA, USA |
| | WMM3 | MODELING SEQUENTIAL DECISION MAKING IN PHARMACOECONOMICS
Bala MV1, Zarkin GA2, 1Centocor, Inc., Malvern, PA, USA; 2Research Triangle Institute, Research Triangle Park, NC, USA |
| | WMS3
| SOFTWARE FOR COST-EFFECTIVENESS STATISTICAL INFERENCE
Obenchain R, Lilly Research Laboratories, Indianapolis, IN, USA |
| | WMS4
| STATISTICAL ISSUES IN THE DESIGNING AND ANALYZING THE DATA FOR PHARMACOECONOMICS AND OUTCOMES STUDIES
Rajagopalan R, Glaxo Wellcome Inc, Research Triangle Park, NC, USA; University of North Carolina School of Pharmacy, Chapel Hill, NC, USA |
| | WMD2
| THE WHAT, HOW, AND WHY OF THE DELPHI
Downs K, Richter A, Research Triangle Institute, Research Triangle Park, NC, USA |
| | WMD3
| NEW METHODS OF DATA COLLECTION IN THE COMMUNITY-BASED PHYSICIAN SETTING - PROCESS AND TECHNOLOGY
Jardina P, Irwin C, Physicians Data Corporation, Atlanta, GA, USA |
| | WMQ2
| A GUIDE FOR SELECTING HEALTH OUTCOMES AND QUALITY OF LIFE MEASURES
Erickson P, The On-Line Guide to Quality-of-Life Assessment (OLGA), and Department of Health Evaluation Sciences, Hershey Medical Center, Penn State University, State College, PA, USA |
|
| 4:00 - 4:50PM | CONTRIBUTED WORKSHOPS - SESSION 2R
(A repeat of SESSION 2 workshops) |
|
| 5:00PM - 7:00PM | EXHIBIT/POSTER SHOWCASE RECEPTION |
| 7:00PM - 9:00PM | ISPOR STUDENT NETWORKING FORUM & PIZZA PARTY
Reception sponsored by Hoechst Marion Roussel
EMPLOYMENT OPPORTUNITIES IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
Presented by: Jean Paul Gagnon PhD, Director, Health Economics Policy, Hoechst Marion Roussel, Kansas City, MO, USA and ISPOR Treasurer |
Annual International Meeting Main Page
|
|
|
|
|
